NCT01944839View on ClinicalTrials.gov

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

PHASE3TerminatedINTERVENTIONAL
Enrollment

619

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

E10030

DRUG

ranibizumab

DRUG

E10030 sham intravitreal injection

Pressure on the eye with a syringe with no needle

Trial Locations (115)

1000

Lausanne

1090

Vienna

2100

Deurne

3000

Leuven

3010

Bern

4021

Linz

4102

Basel

6020

Innsbruck

8036

Graz

8063

Zurich

10122

Torino

10138

Tallinn

11021

Great Neck

11412

Harju

11967

Shirley

15212

Pittsburgh

17011

Camp Hill

19107

Philadelphia

20122

Milan

20132

Milan

20157

Milan

20815

Chevy Chase

22031

Fairfax

29456

Ladson

30060

Marietta

32701

Altamonte Springs

33100

Udine

33609

Tampa

33612

Tampa

33880

Winter Haven

33907

Fort Myers

34233

Sarasota

35128

Padua

37232

Nashville

40138

Bologna

40202

Louisville

40509

Lexington

40536

Lexington

44121

Ferrara

44195

Cleveland

45242

Cincinnati

46290

Indianapolis

48034

Southfield

49202

Jackson

50134

Florence

51003

Tartu

53705

Madison

55905

Rochester

60126

Ancona

63110

St Louis

66211

Leawood

70121

New Orleans

74210

Goiânia

75701

Tyler

78705

Austin

79606

Abilene

80909

Colorado Springs

84132

Salt Lake City

85014

Phoenix

87109

Albuquerque

89135

Las Vegas

90095

Los Angeles

90211

Beverly Hills

90440

Porto Alegre

91171

Trenčín

93103

Santa Barbara

93309

Bakersfield

94107

San Francisco

97520

Ashland

06606

Bridgeport

06320

New London

62704-2173

Springfield

02111

Boston

02114

Boston

03801

Portsmouth

08225

Northfield

30150-270

Minas Gerais

01525-001

São Paulo

04021-050

São Paulo

04023-062

São Paulo

T2H 0C8

Calgary

V5Z 3N9

Vancouver

R3P 1A2

Winnipeg

B3H 2Y9

Halifax

N6A 4V2

London

L4W 1W9

Mississauga

K1H 8L6

Ottawa

M4N 3M5

Toronto

M5T 2S8

Toronto

H3A 1A1

Montreal

S7K 0M7

Saskatoon

625 00

Brno

500 05

Kralovice

401 13

Libeň

775 20

Olomouc

10 100 34

Prague

6 169 02

Prague

00133

Roma

00198

Roma

LV-1050

Riga

LV-11002

Riga

85-631

Bydgoszcz

43-300

Katowice

91 -134

Lodz

02005

Warsaw

50-556

Wroclaw

975 17

Banská Bystrica

826 06

Bratislava

BT12 6BA

Belfast

L7 8XP

Liverpool

EC1V 2PD

London

SE5 9RS

London

PL6 8DH

Plymouth

SO16 6YD

Southampton

GU17UJ

Surrey Quays

Sponsors
All Listed Sponsors
lead

Ophthotech Corporation

INDUSTRY

NCT01944839 - A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy | Biotech Hunter | Biotech Hunter